Shares of OncoGenex Pharmaceuticals Inc. soared 75.6 percent on Wednesday thanks to positive survival data from a Phase II trial of lead compound OGX-011 in the first-line treatment of hormone refractory prostate cancer (HRPC). (BioWorld Today) Read More